Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CVS Health Corp (NY:CVS)

62.47 +0.37 (+0.60%)
Official Closing Price Updated: 7:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CVS Health Corp

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
59 60 Next >
U.S. Weekly Fundflows Insight Report: Equity ETFs, Conventional Funds Suffer Net Redemptions For The Fund-Flows Week
Investors were net sellers of fund assets (including those of conventional funds and ETFs) for the second week in three, redeeming a net $15.7 billion for the LSEG Lipper fund-flows week ended... 
Via Talk Markets
Topics ETFs
What's Going On With Health Insurance Firm UnitedHealth Stock Today?
Explore UnitedHealth Group Inc stock insights! Discover recent market trends, CEO perspectives, and financial highlights. 
Via Benzinga
Critical Insights From CVS Health Analyst Ratings: What You Need To Know
 
Via Benzinga
The 3 Most Undervalued Stocks With Strong Fundamentals to Buy in February 2024
If you are on the hunt for undervalued stocks, look no further than these three companies with strong fundamentals. 
Via InvestorPlace
CVS Health (CVS) Q4 2023 Earnings Call Transcript
CVS earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
CVS Beats Q4 Forecasts with $93.8B Revenue and $2.12 EPS
CVS Health Corp. reported a successful Q4 2023, achieving $93.8 billion in revenue. 
Via Talk Markets
Earnings Scheduled For February 7, 2024
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million. 
Via Benzinga
Earnings Preview: CVS Health
 
Via Benzinga
What the Options Market Tells Us About CVS Health
 
Via Benzinga
S&P 500 Flirts With 5,000 As Magnificent 7 Tops $13 Trillion, NYCB Sinks: What's Driving Markets Wednesday?
Wednesday is a bullish day on Wall Street, with major large-cap indices extending record highs, aided by robust corporate earnings. Despite the overall market optimism, concerns linger within segments... 
Via Benzinga
Topics Stocks
CVS Health's Q4 Earnings Relieve Investor Concerns But Lowers 2024 Profit Guidance Citing Elevated Medical Cost Trends
CVS Health beats Q4 expectations with $2.12 adjusted EPS, allays concerns over healthcare costs. Sales rise 11.9% to $93.81 billion. 
Via Benzinga
Nasdaq, S&P 500 Futures Stall As Rate Worries Dampen Earnings Cheer: Why This Analyst Isn't Worried 'Too Much' About Short-Term Risks
The focus once again shifts to speeches by Federal Reserve officials, as traders seek clarity on the potential schedule for rate cuts. 
Via Benzinga
Topics Economy Stocks
CVS Health Unusual Options Activity For February 02
 
Via Benzinga
The 3 Most Undervalued S&P 500 Stocks to Buy in February 2024
With undervalued S&P 500 stocks, you get the best of both worlds: the confidence from large-cap companies and a credible bargain. 
Via InvestorPlace
Topics Stocks
The 7 Most Undervalued Large-Cap Stocks to Buy in February 2024
All eyes are on the 'Magnificent Seven," but these seven undervalued large-cap stocks may be worth considering instead. 
Via InvestorPlace
The 3 Most Undervalued Long-Term Stocks to Buy in February 2024
These undervalued stocks for February 2024 are priced for decline, yet they are thriving businesses participating in key growth trends. 
Via InvestorPlace
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
Check Out What Whales Are Doing With CVS
 
Via Benzinga
Wall Street Favorites: 3 Undervalued Stocks With Strong Buy Ratings for January 2024
Although it may be tempting to ride the coattails of the usual suspects, investors should consider undervalued stocks January 2024. 
Via InvestorPlace
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions. 
Via Benzinga
Did You Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts?
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Humana EPS shocker. Are Medicare Advantage plans in jeopardy?
Humana shares are falling after the health insurance carrier reported a bombshell when it cut its 2024 and 2025 earnings guidance 
Via MarketBeat
Wall Street HATES These Three Stocks
Professional investors on Wall Street are betting against a handful of consumer stocks. 
Via Talk Markets
Fortune 100 Giant Tyson Foods Breaks Ties With CVS Caremark, Marks Shift Towards Transparent Pharmacy Benefit Managers
Tyson Foods shifts from CVS Caremark to startup Rightway, targeting a 15% reduction in pharmacy costs. Explore Tyson's move and its impact on the pharmacy benefits landscape. 
Via Benzinga
Humana Blames Medicare Advantage As Stock Falls After Larger Than Expected Quarterly Loss, Grim Outlook
Humana faces challenges as Q4 2023 earnings disappoint. Adjusted EPS loss at $(0.11), revenue at $25.73 billion. 
Via Benzinga
Humana Dives On Huge 2024 Earnings Warning
The health insurer says earnings will be barely half of estimates. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
MarketBeat Week in Review – 1/15 - 1/19
The market continues to bounce back and forth as investors wait on news from the Federal Reserve later this month, but inflation may still be the bigger story 
Via MarketBeat
Topics Economy
EXCLUSIVE: The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker
The "buy everything" sentiment that powered equity indices higher last quarter is over. It's a stock picker's market, Marc Chaikin says. 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.